...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumori. >Early phase Technology Assessment of nanotechnology in oncology.
【24h】

Early phase Technology Assessment of nanotechnology in oncology.

机译：肿瘤学纳米技术的早期技术评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To perform early Technology Assessment (TA) of nanotechnology in oncology. The possibilities of nanotechnology for detection (imaging), diagnosis and treatment of cancer are subject of different research programs where major investments are concerned. As a range of bio- nanotechnologies is expected to enter the oncology field it is relevant to consider the various aspects involved in especially early TA. This article provides two cases of early assessment of (predecessors of) nanotechnologies: Microarray Analysis and Photodynamic Therapy implementation, which methodology can be extrapolated to other nanotechnologies in oncology. Constructive Technology Assessment (CTA) is used for the introduction of technologies that are still in a dynamic phase of development or in an early stage of diffusion. The selection of studied aspects in CTA is based on: clinical aspects (safety, efficacy, and effectiveness), economic (cost-effectiveness), patient related (QoL, ethical/juridical and psychosocial), organizational aspects (diffusion and adoption) and scenario drafting. The features of the technology and the phase of implementation are decisive for choices and timing of the specific aspects to be studied. A framework was drafted to decide on the relevant aspects. In the first case, early implementation of Microarray Analysis; clinical effectiveness, logistics, patient centeredness and scenario drafting were given priority. Related to the diffusion-phase of Photodynamic Therapy however other aspects were evaluated, such as early cost-effectiveness analysis for possible reimbursement. Often CTA will result in a mixed method design. Especially scenario drafting is a powerful instrument to predict possible developments that can be anticipated upon in the assessment. CTA is appropriate for the study of early implementation of new technologies in oncology. In early TA small series often necessitate a mix of quantitative and qualitative methods. The features of nanotechnology involved are decisive for the selection of CTA aspects, most likely: safety -especially possible interactions with other technologies-, ethics, cost-effectiveness and patient centeredness.
机译：进行肿瘤学纳米技术的早期技术评估（TA）。纳米技术用于检测（成像），诊断和治疗癌症的可能性是涉及重大投资的不同研究计划的主题。随着一系列生物纳米技术有望进入肿瘤学领域，有必要考虑特别是早期技术援助所涉及的各个方面。本文提供了两种对纳米技术（其前身）进行早期评估的案例：微阵列分析和光动力疗法的实施，这些方法可以外推到肿瘤学中的其他纳米技术。建设性技术评估（CTA）用于引入仍处于动态发展阶段或处于扩散初期的技术。在CTA中研究的方面的选择基于：临床方面（安全性，有效性和有效性），经济方面（成本效益），患者相关方面（QoL，伦理/司法和社会心理方面），组织方面（扩散和采用）和情景起草。技术的特征和实施阶段对于要研究的特定方面的选择和时机至关重要。起草了一个框架来决定相关方面。在第一种情况下，尽早实施微阵列分析;临床效果，后勤，以患者为中心和方案起草被优先考虑。与光动力疗法的扩散阶段有关，但是还评估了其他方面，例如对可能的费用进行早期成本效益分析。 CTA通常会导致混合方法设计。尤其是，方案起草是预测评估中可以预期的可能发展的有力工具。 CTA适用于研究肿瘤新技术的早期实施。在早期的技术援助中，小规模的研究通常需要混合使用定量和定性方法。所涉及的纳米技术的特征对于选择CTA方面具有决定性，最可能的是：安全性-尤其是与其他技术的可能相互作用-道德，成本效益和以患者为中心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号